Literature DB >> 17416213

Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces.

G Zorza1, J C Van Heugen, J De Graeve, C Puozzo.   

Abstract

A sensitive and specific liquid chromatographic method coupled with tandem mass spectrometric detection was set up and fully validated for the simultaneous quantification of vinflunine (VFL) and its pharmacologically active metabolite, 4-O-deacetyl vinflunine (DVFL). The two compounds, as well as vinblastine (used as internal standard), were deproteinised from blood and faeces, analysed on a cyano type column and detected on a Micromass Quattro II system in the positive ion mode after ionisation using an electrospray ion source. In blood, linearity was assessed up to 200 ng/ml for vinflunine and 100 ng/ml for 4-O-deacetyl vinflunine. The lower limit of quantification was validated at 250 pg/ml for both compounds. In other biological media, the linearity was assessed within the same range; the limit of quantification was adjusted according to the expected concentration levels of each compound. This method was first developed in order to identify the structures and to elucidate the metabolic pathway of vinflunine. Thanks to its high sensitivity and specificity, the method has enabled the quantification of vinflunine and 4-O-deacetyl vinflunine in blood at trace levels, and has contributed to the knowledge of vinflunine metabolism by monitoring up to 10 metabolites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416213     DOI: 10.1016/j.jchromb.2007.03.030

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

Review 1.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

2.  How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.

Authors:  Nicolas Isambert; Jean Pierre Delord; Jean Marc Tourani; Pierre Fumoleau; Alain Ravaud; Marie Claire Pinel; Aurelie Petain; Thierry Nguyen; Laurent Nguyen
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

3.  Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.

Authors:  M Krzakowski; J Bennouna; E Dansin; D Kowalski; S Hiret; N Penel; S Favrel; J M Tourani
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-13       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.